Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
RESEARCH TOOLSreports
GUTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $7.89
Previous Close$1.96
Volume269.01K
Average Volume (3M)196.82K
Market Cap
$60.66M
Enterprise Value$99.64M
Total Cash (Recent Filing)$67.46M
Total Debt (Recent Filing)$62.50M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
May 19, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding48,920,220
10 Day Avg. Volume156,190
30 Day Avg. Volume196,824
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)657.53
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.32K
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$8.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Fractyl Health, Inc. News
PremiumCompany Announcements
Fractyl Health’s Earnings Call: Progress Amid ChallengesPremiumCompany Announcements
Fractyl Health Reports 2024 Financial Results and Strategic ProgressPremiumCompany Announcements
Fractyl Health Reprioritizes Focus on REMAIN-1 StudyPremiumCompany Announcements
Fractyl Health’s Promising Progress in Weight Management---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe lead program Revita in weight maintenance remains the key driver and continues to rapidly advance in the Ph3 REMAIN-1 study.
Financial StabilityThe restructuring is expected to extend the company's cash runway, providing more financial stability.
Market OpportunityFractyl Health is focusing on obesity treatment, which is expected to provide a significant market opportunity.
Bears Say
Operational AdjustmentsThe pause in diabetes research and workforce reduction reflects a strategic shift due to demand and financial considerations.
Strategic ChallengesThe decision to pause the diabetes program and reduce workforce reflects challenges in this area.
---
Ownership Overview
17.00% Insiders
5.51% Mutual Funds
37.32% Other Institutional Investors
34.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $1.16 and its highest was $7.89 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $60.66M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is May 19, 2025 which is in 49 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Mar 03, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.085.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.45.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 48,920,220 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
---
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (545.16% Upside)
$8.00 (545.16% Upside)
Hedge Fund Trend
Increased
By 33.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $103.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.81%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
---
GUTS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements including regulatory approvals, strong study enrollments, and promising early results from clinical trials. Despite financial losses and coverage challenges for GLP-1 treatments, the advancements in the Revita and Rejuva platforms suggest a promising future for Fractyl's solutions in weight maintenance and metabolic health.Read More>---
GUTS Stock 12 Month Forecast
Average Price Target
$8.00
▲(545.16% Upside)
Technical Analysis
Exact Sciences
―
Pacific Biosciences
―
QuidelOrtho
―
Guardant Health
―
TransMedics Group
―
Best Analysts Covering GUTS
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-62.99%
reiterated a buy rating 2 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -62.99% per trade.
---